BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Wang TE, Kao CR, Lin SC, Chang WH, Chu CH, Lin J, Hsieh RK. Salvage therapy for hepatocellular carcinoma with thalidomide. World J Gastroenterol 2004; 10(5): 649-653 [PMID: 14991931 DOI: 10.3748/wjg.v10.i5.649]
URL: https://www.wjgnet.com/1007-9327/full/v10/i5/649.htm
Number Citing Articles
1
Her-Shyong Shiah, Yee Chao, Li-Tzong Chen, Tzy-Jyun Yao, Jin-Ding Huang, Jang-Yang Chang, Pei-Jer Chen, Tsai-Rong Chuang, Yung-Hsin Chin, Jacqueline Whang-Peng, Tsang-Wu Liu. Phase I and pharmacokinetic study of oral thalidomide in patients with advanced hepatocellular carcinomaCancer Chemotherapy and Pharmacology 2006; 58(5): 654 doi: 10.1007/s00280-006-0203-z
2
Peng Lv, Shelley Chireyath Paul, Yanjv Xiao, Shiquan Liu, Hesheng Luo. Effects of Thalidomide on the Expression of Adhesion Molecules in Rat Liver CirrhosisMediators of Inflammation 2006; 2006: 1 doi: 10.1155/MI/2006/93253
3
Chun-Chieh Yeh, Jaw-Town Lin, Long-Bin Jeng, Hsiu J. Ho, Horng-Ren Yang, Ming-Shiang Wu, Ken N. Kuo, Chun-Ying Wu. Nonsteroidal Anti-inflammatory Drugs Are Associated With Reduced Risk of Early Hepatocellular Carcinoma Recurrence After Curative Liver ResectionAnnals of Surgery 2015; 261(3): 521 doi: 10.1097/SLA.0000000000000746
4
Ching-Wei Chang, Tsang-En Wang, Li-Tzong Chen, Wen-Hsiung Chang, Yi-Shing Leu, Yang-Kai Fan, Yu-Jan Chan. Unusual presentation of metastatic hepatocellular carcinoma in the nasal septum: a case report and review of the literatureMedical Oncology 2008; 25(3): 264 doi: 10.1007/s12032-007-9028-9
5
Chapter 4: Chemotherapy and radiotherapyHepatology Research 2010; 40(s1): 74 doi: 10.1111/j.1872-034X.2010.00657.x
6
Andrew X. Zhu. Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be?The Oncologist 2006; 11(7): 790 doi: 10.1634/theoncologist.11-7-790
7
Chul Ju Han. Recent developments in systemic chemotherapy for hepatocellular carcinomaThe Korean Journal of Hepatology 2008; 14(1): 4 doi: 10.3350/kjhep.2008.14.1.4
8
Magnus Rizell, Mats Andersson, Christian Cahlin, Larsolof Hafström, Michael Olausson, Per Lindnér. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancerInternational Journal of Clinical Oncology 2008; 13(1): 66 doi: 10.1007/s10147-007-0733-3
9
Melanie Thomas. Molecular targeted therapy for hepatocellular carcinomaJournal of Gastroenterology 2009; 44(S19): 136 doi: 10.1007/s00535-008-2252-z
10
Jonathan D. Schwartz, Josep M. Llovet. Molecular Targeting in OncologyCancer Drug Discovery and Development 2008; : 165 doi: 10.1007/978-1-59745-337-0_8
11
Yu-Yun Shao, Ann-Lii Cheng, Chih-Hung Hsu. Metronomic Chemotherapy2014; : 189 doi: 10.1007/978-3-662-43604-2_13
12
Ahmed Kaseb, Melanie Thomas. Hepatocellular Carcinoma2009; : 114 doi: 10.3109/9780203092880-10
13
Domenico Ribatti, Angelo Vacca, Beatrice Nico, Domenico Sansonno, Franco Dammacco. Angiogenesis and anti-angiogenesis in hepatocellular carcinomaCancer Treatment Reviews 2006; 32(6): 437 doi: 10.1016/j.ctrv.2006.06.002
14
Shin‐Cherng Chen, Hui‐Jen Tsai, Chang‐Ming Jan, Yi‐Hui Wang, Li‐Tzong Chen. Low dose of thalidomide can be effective in advanced hepatocellular carcinomaJournal of Gastroenterology and Hepatology 2006; 21(12): 1868 doi: 10.1111/j.1440-1746.2006.04303.x
15
William Sanchez, Jayant A. Talwalkar. Palliative Care for Patients with End-Stage Liver Disease Ineligible for Liver TransplantationGastroenterology Clinics of North America 2006; 35(1): 201 doi: 10.1016/j.gtc.2005.12.007
16
Hsueh-Erh Chiou, Tsang-En Wang, Ying-Yue Wang, Hui-Wen Liu. Efficacy and safety of thalidomide in patients with hepatocellular carcinomaWorld Journal of Gastroenterology 2006; 12(43): 6955-6960 doi: 10.3748/wjg.v12.i43.6955
17
L.‐T. CHEN, T.‐W. LIU, Y. CHAO, H.‐S. SHIAH, J.‐Y. CHANG, S.‐H. JUANG, S.‐C. CHEN, T.‐R. CHUANG, Y.‐H. CHIN, J. WHANG‐PENG. α‐fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinomaAlimentary Pharmacology & Therapeutics 2005; 22(3): 217 doi: 10.1111/j.1365-2036.2005.02547.x
18
Sang Hoon Han, Se Hoon Park, Jung Ho Kim, Jong Jun Lee, So Young Kwon, Oh Sang Kwon, Sun Suk Kim, Ju Hyun Kim, Keon Kug Kim, Yeon Ho Park, Jeong Nam Lee, Eunmi Nam, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee. Thalidomide for Treating Metastatic Hepatocellular Carcinoma: A Pilot StudyThe Korean Journal of Internal Medicine 2006; 21(4): 225 doi: 10.3904/kjim.2006.21.4.225
19
David Semela, Jean-François Dufour. Angiogenesis and hepatocellular carcinomaJournal of Hepatology 2004; 41(5): 864 doi: 10.1016/j.jhep.2004.09.006
20
A. Ponferrada, M. Salcedo, A. Matilla, O. Núñez, R. Bañares, E. Álvarez, G. Clemente. Heterogeneidad clínica y evolutiva del hemangioendotelioma epitelioide hepáticoGastroenterología y Hepatología 2005; 28(6): 321 doi: 10.1157/13076348
21
Tsang‐En WANG, Ken‐Hong LIM, Ming‐Jer HUANG. Combined thalidomide and interferon‐α for chronic hepatitis C‐related hepatocellular carcinomaAsia-Pacific Journal of Clinical Oncology 2007; 3(1): 52 doi: 10.1111/j.1743-7563.2006.00082.x
22
Stefan Sleijfer, Wim H.J. Kruit, Gerrit Stoter. Thalidomide in solid tumours: the resurrection of an old drugEuropean Journal of Cancer 2004; 40(16): 2377 doi: 10.1016/j.ejca.2004.07.023
23
Benjamin Chuah, Robert Lim, Michael Boyer, Ai-Bee Ong, Seng-Weng Wong, Hwai-Loong Kong, Michael Millward, Stephen Clarke, Boon-Cher Goh. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinomaActa Oncologica 2007; 46(2): 234 doi: 10.1080/02841860600702076
24
Andrew X. Zhu, Charles S. Fuchs, Jeffrey W. Clark, Alona Muzikansky, Kerry Taylor, Susan Sheehan, Kayao Tam, Elizabeth Yung, Matthew H. Kulke, David P. Ryan. A Phase II Study of Epirubicin and Thalidomide in Unresectable or Metastatic Hepatocellular CarcinomaThe Oncologist 2005; 10(6): 392 doi: 10.1634/theoncologist.10-6-392
25
Lars A Ormandy, Anatol Färber, Tobias Cantz, Susanne Petrykowska, Heiner Wedemeyer, Monique Hörning, Frank Lehner, Michael P Manns, Firouzeh Korangy, Tim F Greten. Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinomaWorld Journal of Gastroenterology 2006; 12(20): 3275-3282 doi: 10.3748/wjg.v12.i20.3275
26
Chiun Hsu, Chiung-Nien Chen, Ann-Lii Cheng. Liver Cancer2009; : 277 doi: 10.1007/978-1-4020-9804-8_21
27
Yehuda Z. Patt, Manal M. Hassan, Richard D. Lozano, Ajay K. Nooka, Isaac I. Schnirer, Jerome B. Zeldis, James L. Abbruzzese, Thomas D. Brown. Thalidomide in the treatment of patients with hepatocellular carcinomaCancer 2005; 103(4): 749 doi: 10.1002/cncr.20821
28
Matthias Pinter, Martina Wichlas, Katharina Schmid, Christina Plank, Christian Müller, Friedrich Wrba, Markus Peck-Radosavljevic. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trialEuropean Journal of Gastroenterology & Hepatology 2008; 20(10): 1012 doi: 10.1097/MEG.0b013e3283036740
29
Dimitris Zacharoulis, Constantine Hatzitheofilou, Evangelos Athanasiou, Stergios Zacharoulis. Antiangiogenic strategies in hepatocellular carcinoma: current statusExpert Review of Anticancer Therapy 2005; 5(4): 645 doi: 10.1586/14737140.5.4.645
30
Jonathan D. Schwartz, Max Sung, Myron Schwartz, Deborah Lehrer, John Mandeli, Leonard Liebes, Alec Goldenberg, Matthew Volm. Thalidomide in Advanced Hepatocellular Carcinoma with Optional Low-Dose Interferon-α2a upon ProgressionThe Oncologist 2005; 10(9): 718 doi: 10.1634/theoncologist.10-9-718
31
Austin Duffy, Tim Greten. Developing better treatments in hepatocellular carcinomaExpert Review of Gastroenterology & Hepatology 2010; 4(5): 551 doi: 10.1586/egh.10.58